Novel drug delivery technologies
IriSys develops formulations for new chemical entities and ANDA/generic products. We also have experience developing formulations with 505(b)(2) product candidates, which can rely in part on data from existing reference drugs. Our formulations can support the expansion of our clients’ intellectual property portfolios.
Micro and nanoparticles
Liposomes, microspheres and micelles
Controlled release formulations
Controlled release solid dosages